These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 33646044)
21. Structure of Zhou S; Wang W; Zhou X; Zhang Y; Lai Y; Tang Y; Xu J; Li D; Lin J; Yang X; Ran T; Chen H; Guddat LW; Wang Q; Gao Y; Rao Z; Gong H Elife; 2021 Nov; 10():. PubMed ID: 34819223 [TBL] [Abstract][Full Text] [Related]
22. Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients. Gao J; Pei Y; Yan X; Shi G; Li T; Gao M; Liu Y; Wang Y; Shu W; Li L; Pang Y Int J Infect Dis; 2020 Nov; 100():196-198. PubMed ID: 32890726 [TBL] [Abstract][Full Text] [Related]
24. Isolation and characterization of nontuberculous mycobacteria from patients with pulmonary tuberculosis in Ghana. Otchere ID; Asante-Poku A; Osei-Wusu S; Aboagye SY; Yeboah-Manu D Int J Mycobacteriol; 2017; 6(1):70-75. PubMed ID: 28317808 [TBL] [Abstract][Full Text] [Related]
25. The QcrB Inhibitors TB47 and Telacebec Do Not Potentiate the Activity of Clofazimine in Mycobacterium abscessus. Sorayah R; Moraski GC; Barkan D; Pethe K Antimicrob Agents Chemother; 2021 Nov; 65(12):e0096421. PubMed ID: 34543090 [TBL] [Abstract][Full Text] [Related]
26. Response of Chauhan P; van der Meulen SA; Simões Caetano JM; Goojani HG; Botman D; van Spanning R; Lill H; Bald D Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142240 [TBL] [Abstract][Full Text] [Related]
27. The Epidemiology of first and second-line drug-resistance Mycobacterium tuberculosis complex common species: Evidence from selected TB treatment initiating centers in Ethiopia. Dagne B; Desta K; Fekade R; Amare M; Tadesse M; Diriba G; Zerihun B; Getu M; Sinshaw W; Seid G; Gamtesa DF; Assefa G; Alemu A PLoS One; 2021; 16(1):e0245687. PubMed ID: 33507946 [TBL] [Abstract][Full Text] [Related]
28. Meropenem-clavulanate has high in vitro activity against multidrug-resistant Mycobacterium tuberculosis. Davies Forsman L; Giske CG; Bruchfeld J; Schön T; Juréen P; Ängeby K Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():80-1. PubMed ID: 27128620 [TBL] [Abstract][Full Text] [Related]
29. Differences in risk factors and drug susceptibility between Mycobacterium avium and Mycobacterium intracellulare lung diseases in China. Zhang Z; Pang Y; Wang Y; Cohen C; Zhao Y; Liu C Int J Antimicrob Agents; 2015 May; 45(5):491-5. PubMed ID: 25795316 [TBL] [Abstract][Full Text] [Related]
30. Effect of Mixed Infections with Huang M; Tan Y; Zhang X; Wang Y; Su B; Xue Z; Wang J; Pang Y Infect Drug Resist; 2022; 15():157-166. PubMed ID: 35082503 [TBL] [Abstract][Full Text] [Related]
31. In vitro Susceptibility of Nontuberculous Mycobacteria to Tedizolid. Zhang H; Hua W; Lin S; Zhang Y; Chen X; Wang S; Chen J; Zhang W Infect Drug Resist; 2022; 15():4845-4852. PubMed ID: 36045871 [TBL] [Abstract][Full Text] [Related]
33. [Frequently Isolated Slow Growing Nontuberculous Mycobacteria from Pulmonary Samples and Evaluation of Drug Susceptibility Testing Results in a Referral Hospital in Turkey]. Ceyhan İ; Özkara Ş; Güler MZ; Dulkar G; Altınsoy R; Vezir S Mikrobiyol Bul; 2019 Jul; 53(3):330-335. PubMed ID: 31414634 [TBL] [Abstract][Full Text] [Related]
34. Genotyping and drug susceptibility testing of mycobacterial isolates from population-based tuberculosis prevalence survey in Ghana. Addo KK; Addo SO; Mensah GI; Mosi L; Bonsu FA BMC Infect Dis; 2017 Dec; 17(1):743. PubMed ID: 29197331 [TBL] [Abstract][Full Text] [Related]
35. In-vitro activity of quinolones and macrolides against mycobacteria. Yew WW; Piddock LJ; Li MS; Lyon D; Chan CY; Cheng AF J Antimicrob Chemother; 1994 Sep; 34(3):343-51. PubMed ID: 7829409 [TBL] [Abstract][Full Text] [Related]
36. Genotyping and clinical characteristics of multidrug and extensively drug-resistant tuberculosis in a tertiary care tuberculosis hospital in China. Yuan X; Zhang T; Kawakami K; Zhu J; Zheng W; Li H; Deng G; Tu S; Liu W BMC Infect Dis; 2013 Jul; 13():315. PubMed ID: 23849244 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of 12 antimicrobial peptides against Mycobacterium tuberculosis and Mycobacterium avium clinical isolates. Portell-Buj E; Vergara A; Alejo I; López-Gavín A; Monté MR; San Nicolás L; González-Martín J; Tudó G J Med Microbiol; 2019 Feb; 68(2):211-215. PubMed ID: 30570475 [TBL] [Abstract][Full Text] [Related]
38. Antimicrobial susceptibility and molecular characterization of Mycobacterium intracellulare in China. Zhao X; Wang Y; Pang Y Infect Genet Evol; 2014 Oct; 27():332-8. PubMed ID: 25131955 [TBL] [Abstract][Full Text] [Related]
39. Isolation of non-tuberculous mycobacteria among tuberculosis patients, a study from a tertiary care hospital in Lahore, Pakistan. Karamat A; Ambreen A; Ishtiaq A; Tahseen S; Rahman MA; Mustafa T BMC Infect Dis; 2021 Apr; 21(1):381. PubMed ID: 33894767 [TBL] [Abstract][Full Text] [Related]
40. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo. Koga T; Fukuoka T; Doi N; Harasaki T; Inoue H; Hotoda H; Kakuta M; Muramatsu Y; Yamamura N; Hoshi M; Hirota T J Antimicrob Chemother; 2004 Oct; 54(4):755-60. PubMed ID: 15347635 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]